Boston Convention and Exhibition Center
November 11-15, 2025
OncoCore™ DNA+RNA
Because Waiting Shouldn't Be Part of Your Oncology Plan
Created for fast access to actionable precision oncology, OncoCore™ is an advanced 32-gene NGS panel that uses targeted amplicon sequencing to analyze both DNA and RNA, detecting all clinically significant single nucleotide variants (SNVs), insertions and deletions (InDels), gene fusions, and microsatellite instability (MSI).
OncoCore™ incorporates microfluidic devices to achieve full automation and provides results within a rapid 3-4 day turnaround. This swift processing provides clinicians with essential, timely data to inform immunotherapy treatment decisions for their patients.
OncoCore™ incorporates microfluidic devices to achieve full automation and provides results within a rapid 3-4 day turnaround. This swift processing provides clinicians with essential, timely data to inform immunotherapy treatment decisions for their patients.
- Fast, Actionable, 32 Gene Panel
- Results within 3-4 days
- Provides coverage of cancer-relevant biomarkers cross DNA and RNA in a single assay
- Broad and deep sequencing coverage accurately detects mutations, rare fusions, and transcript variants
- Clinical Utility
- Comprehensive detection of actionable mutations, insertions, deletions, and gene fusions is critical for treatment decisions
- Provides a complete solution by identifying all actionable genes relevant to FDA-approved therapies
- Versatile testing applicable to all major types of solid tumors, enhancing diagnostic precision
Automated process
FFPE block
Extraction
of DNA and RNA
of DNA and RNA
Library construction
Sequencing
Day 1
Day 2
Day 3
-
Interrogates 551 SNVs/InDels,
552 Fusions, MSI -
Delivers high accuracy with 100% sensitivity and 100% specificity** if MAF level > 1.0% -
Covers targeted gene mutations for Thyroid, NSCLC, Melanoma, Cholangiocarcinoma, Colorectal, GIST, Urothelial carcinoma and Bladder carcinoma -
Highlights results in an easy-to-interpret report featuring mutations associated with FDA-approved treatments and clinical trial options
Actionable markers
IMMUNOTHERAPY BIOMARKERS:
MSI, MMR, PD-L1
MSI, MMR, PD-L1
-
ThyroidBRAF, RAS, TP53, RET -
Non-small cell lung cancer (NSCLC)ALK, BRAF, EGFR, ERBB2(HER2), KRAS, MET, NTRK1, NTRK2, NTRK3, RET, ROS1 -
CholangiocarcinomaBRAF, FGFR2, IDH1, NRG1, NTRK1, NTRK2, NTRK3, RET -
Gastrointestinal stromal tumor (GIST)KIT, NTRK1, NTRK2, NTRK3, PDGFRA -
Colorectal Cancer (CRC)BRAF, KRAS, NRAS, NTRK1, NTRK2, NTRK3, RET -
Urothelial carcinoma & Bladder carcinomaFGFR2, FGFR3, NTRK1, NTRK2, NTRK3 -
MelanomaALK, BRAF , EGFR, ERBB2(HER2), KRAS, MET, NTRK1, NTRK2, NTRK3, RET, ROS1
Gene list
Genes associated with targeted therapy, prognosis, and drug resistance
Fusion Variants
Drugs recommended by NCCN
Non-small cell lung cancer (NSCLC)
Colorectal cancer (CRC)
For information on additional malignancies recommended by the NCCN, please contact us directly.
